News articles about Spark Therapeutics (NASDAQ:ONCE) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Spark Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.6137727575068 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the media stories that may have effected Accern Sentiment’s scoring:

Shares of Spark Therapeutics (NASDAQ:ONCE) traded up $2.55 during trading on Friday, reaching $52.75. The company’s stock had a trading volume of 1,217,105 shares, compared to its average volume of 1,350,000. The stock has a market cap of $2,050.00 and a PE ratio of -7.33. Spark Therapeutics has a 1-year low of $41.06 and a 1-year high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). The company had revenue of $1.90 million during the quarter, compared to analysts’ expectations of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. Spark Therapeutics’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same period last year, the firm earned ($1.07) earnings per share. equities analysts anticipate that Spark Therapeutics will post -7.6 earnings per share for the current year.

ONCE has been the subject of a number of research analyst reports. Jefferies Group reiterated a “buy” rating and set a $95.00 price target on shares of Spark Therapeutics in a research report on Tuesday, October 10th. SunTrust Banks set a $101.00 price target on Spark Therapeutics and gave the company a “buy” rating in a research report on Monday, October 16th. BMO Capital Markets reiterated a “buy” rating and set a $101.00 price target on shares of Spark Therapeutics in a research report on Wednesday, November 15th. Cowen restated a “buy” rating and issued a $95.00 target price on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Finally, Royal Bank of Canada dropped their target price on Spark Therapeutics from $100.00 to $98.00 and set an “outperform” rating for the company in a research report on Wednesday, November 8th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $76.19.

In other Spark Therapeutics news, insider Daniel Faga sold 7,500 shares of Spark Therapeutics stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $80.96, for a total value of $607,200.00. Following the transaction, the insider now directly owns 6,000 shares of the company’s stock, valued at approximately $485,760. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Katherine A. High sold 5,000 shares of Spark Therapeutics stock in a transaction that occurred on Tuesday, September 26th. The stock was sold at an average price of $86.16, for a total value of $430,800.00. Following the completion of the transaction, the insider now directly owns 215,000 shares in the company, valued at $18,524,400. The disclosure for this sale can be found here. Insiders sold a total of 67,309 shares of company stock worth $5,051,885 over the last ninety days. Insiders own 7.30% of the company’s stock.

WARNING: “Spark Therapeutics (ONCE) Getting Somewhat Positive Media Coverage, Report Shows” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://theolympiareport.com/2017/12/24/spark-therapeutics-once-getting-somewhat-positive-media-coverage-report-shows.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.